6-hydroxy-3-(1-(2-(naphthalen-1-ylamino)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)-2-phenylbenzofuran-5-carboxylic acid | 1226906-81-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 2-芳基苯并呋喃类黄酮
• 英文名称: 6-hydroxy-3-(1-(2-(naphthalen-1-ylamino)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)-2-phenylbenzofuran-5-carboxylic acid
• 英文别名: 6-hydroxy-3-[1-[2-(naphthalen-1-ylamino)-2-oxoethyl]triazol-4-yl]-2-phenyl-1-benzofuran-5-carboxylic acid
• CAS: 1226906-81-5
• 化学式: C₂₉H₂₀N₄O₅
• 分子量: 504.502
• InChiKey: DGPJPGIEQRCUGI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  38
• 可旋转键数：
  6
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.03
• 拓扑面积：
  131
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  在 copper(ll) sulfate pentahydrate 、 L-ascorbic acid sodium salt 、 lithium hydroxide 作用下， 以 甲醇 、 水 、 叔丁醇 为溶剂， 生成 6-hydroxy-3-(1-(2-(naphthalen-1-ylamino)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)-2-phenylbenzofuran-5-carboxylic acid
  参考文献：
  名称：

  Inhibition of Lymphoid Tyrosine Phosphatase by Benzofuran Salicylic Acids

  摘要：

  The lymphoid tyrosine phosphatase (Lyp, PTPN22) is a critical negative regulator of T cell antigen receptor (TCR) signaling. A single-nucleotide polymorphism (SNP) in the ptpn22 gene correlates with the incidence of various autoimmune diseases, including type I diabetes, rheumatoid arthritis, and systemic lupus erythematosus. Since the disease-associated allele is a more potent inhibitor of TCR signaling, specific Lyp inhibitors May become valuable in treating autoimmunity. Using a structure-based approach, we synthesized a library of 34 compounds that inhibited Lyp with IC50 values between 0.27 and 6.2 mu M. A reporter assay was employed to screen for compounds that enhanced TCR signaling in cells, and several inhibitors displayed a dose-dependent, activating effect. Subsequent probing for Lyp's direct physiological targets by immunoblot analysis confirmed the ability of the compounds to inhibit Lyp in T cells. Selectivity profiling against closely related tyrosine phosphatases and in silico docking studies with the crystal structure of Lyp yielded valuable information for the design of Lyp-specific compounds.

  DOI：

  10.1021/jm101004d

文献信息

• Targeting mycobacterium protein tyrosine phosphatase B for antituberculosis agents
  作者：Bo Zhou、Yantao He、Xian Zhang、Jie Xu、Yong Luo、Yuehong Wang、Scott G. Franzblau、Zhenyun Yang、Rebecca J. Chan、Yan Liu、Jianyu Zheng、Zhong-Yin Zhang

  DOI：10.1073/pnas.0909133107

  日期：2010.3.9

  We uncovered that mPTPB subverts the innate immune responses by blocking the ERK1/2 and p38 mediated IL-6 production and promoting host cell survival by activating the Akt pathway. We identified a potent and selective mPTPB inhibitor I-A09 with highly efficacious cellular activity, from a combinatorial library of bidentate benzofuran salicylic acid derivatives assembled by click chemistry. We demonstrated

  蛋白质酪氨酸磷酸酶常被病原菌利用和破坏，引起人类疾病。来自结核分枝杆菌的酪氨酸磷酸酶 mPTPB 是一种必需的毒力因子，由细菌分泌到巨噬细胞的细胞质中，在那里它介导分枝杆菌在宿主中的存活。因此，人们对了解 mPTPB 逃避宿主免疫反应的机制以及开发作为独特抗结核 (antiTB) 药物的强效和选择性 mPTPB 抑制剂具有相当大的兴趣。我们发现 mPTPB 通过阻断 ERK1/2 和 p38 介导的 IL-6 产生并通过激活 Akt 通路促进宿主细胞存活来破坏先天免疫反应。我们鉴定了一种具有高效细胞活性的强效选择性 mPTPB 抑制剂 I-A09，来自通过点击化学组装的双齿苯并呋喃水杨酸衍生物的组合文库。我们证明了在巨噬细胞中用 I-A09 抑制 mPTPB 可以逆转细菌磷酸酶诱导的宿主免疫反应的改变，并防止宿主细胞中的结核病生长。结果提供了必要的原理验证数据，以支持 mPTPB 的特定抑制剂可作为有效的抗结核治疗剂的观点。
• Inhibition of Lymphoid Tyrosine Phosphatase by Benzofuran Salicylic Acids
  作者：Torkel Vang、Yuli Xie、Wallace H. Liu、Dušica Vidović、Yidong Liu、Shuangding Wu、Deborah H. Smith、Alison Rinderspacher、Caty Chung、Gangli Gong、Tomas Mustelin、Donald W. Landry、Robert C. Rickert、Stephan C. Schürer、Shi-Xian Deng、Lutz Tautz

  DOI：10.1021/jm101004d

  日期：2011.1.27

  The lymphoid tyrosine phosphatase (Lyp, PTPN22) is a critical negative regulator of T cell antigen receptor (TCR) signaling. A single-nucleotide polymorphism (SNP) in the ptpn22 gene correlates with the incidence of various autoimmune diseases, including type I diabetes, rheumatoid arthritis, and systemic lupus erythematosus. Since the disease-associated allele is a more potent inhibitor of TCR signaling, specific Lyp inhibitors May become valuable in treating autoimmunity. Using a structure-based approach, we synthesized a library of 34 compounds that inhibited Lyp with IC50 values between 0.27 and 6.2 mu M. A reporter assay was employed to screen for compounds that enhanced TCR signaling in cells, and several inhibitors displayed a dose-dependent, activating effect. Subsequent probing for Lyp's direct physiological targets by immunoblot analysis confirmed the ability of the compounds to inhibit Lyp in T cells. Selectivity profiling against closely related tyrosine phosphatases and in silico docking studies with the crystal structure of Lyp yielded valuable information for the design of Lyp-specific compounds.